Oxidative stress in cyclosporin and azathioprine treated renal transplant patients

Clinica Chimica Acta

Volumn 264, Issue 1, 1997, Pages 1-12

  McGrath, Lawrence T ^a   Treacy, Rita ^b   McClean, Elizabeth ^b   Brown, J Henry ^c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c ANTRIM AREA HOSPITAL   (United Kingdom)

Author keywords

Azathioprine; Cyclosporin; Free radicals; Oxidative stress; Renal transplantation

Indexed keywords

ALPHA TOCOPHEROL; AZATHIOPRINE; CHOLESTEROL; COPPER; CREATININE; CYCLOSPORIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; SELENIUM; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UREA; ZINC;

ADULT; ARTICLE; CELL MEMBRANE FLUIDITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE MEMBRANE; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; ANTIOXIDANTS; AZATHIOPRINE; CYCLOSPORINE; ERYTHROCYTE MEMBRANE; FEMALE; FREE RADICALS; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MEMBRANE FLUIDITY; MIDDLE AGED; OXIDATIVE STRESS; PREDNISOLONE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 0030747941     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(97)00088-0     Document Type: Article

References (50)

1. Rice-Evans CA, Diplock AT, Symons MCR. Techniques in free radical research. In: Burdon RH, Knippenberg PH, editors. Laboratory techniques in biochemistry and molecular biology. London: Elsevier, 1991:1-18.
2. Porter NA. Chemistry of lipid peroxidation. Methods Enzymol 1984;105:273-83.
3. Southorn PS, Powis G. Free radicals in Medicine II: Involvement in human disease. Mayo Clin Proc 1988;63:390-408.
4. Baud L, Ardaillou R. Reactive oxygen species: production and role in the kidney. Am J Physiol 1986;251:F765-76.
5. Shah SV. Role of reactive oxygen metabolises in experimental glomerular disease. Kidney Int 1989;35:1093-106.
6. Descamps-Latscha B, Nguyen AT, Campos H, Droz D, Kreia H, Crosnier J. Investigation of the oxidative metabolism of infiltrating phagocytic cells in human renal allografts. Proc 2nd Int Workshop on Renal Transplantation Cytology. 1984:151-8.
7. Fischer JW, Ohono Y, Barona J, Martinez M, Rege AB. Role of erythropoietin and inhibitors of erythropoiesis in anaemia of renal insufficiency. Dialysis Transplant 1978;7:472-81.
8. Chauchan DP, Gupta PH, Nampoothiri MRN, Singhal PC, Chugh KS, Nair CR. Determination of erythrocyte superoxide dismutase, catalase, glucose-6-phosphate dehydrogenase, reduced glutathione and malonaldehyde in uraemia. Clin Chim Acta 1982;123:153-9.
9. Turan B, Delibasi E, Dalay N, Sert S, Afrasyap L, Sayal A. Serum selenium and glutathione peroxidase activities and their interaction with toxic metals in dialysis and renal transplantation patients. Biological Trace Element Research 1992;33:95-102.
10. Barry JM. Immunosuppressive drugs in renal transplantation. Drugs 1992;44(4):554-66.
11. Hayes J. The immunobiology and clinical use of current immunosuppressive therapy for renal transplantation. J Urol 1993;149:437-48.
12. Strom TB. Immunosuppressive treatments that thwart transplant rejection. Clinical Aspects of Autoimmunity 1990;4:8-19.
13. Opelz G, Schwarz V, Engelman A, Back D, Wilk M. Long-term impact of HLA matching on kidney graft survival in cyclosporin treated recipients. Transplant Proc 1991;23:373.
14. Rossi SJ, Schroeder TJ, Hariharan S, First MR. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Safety 1993;9(2):104-31.
15. European Milticentre Trial Group. Cyclosporin in cadaveric renal transplantation. One year follow-up of a multi-centre trial. Lancet 1983;2:986-9.
16. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporin in cadaveric renal transplantation. N Engl J Med 1983;309:809-15.
17. Hall BM, Tiller DJ, Hardie I, Mahoney J, Mathew J, Thatcher G. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988;318(23):1499-507.
18. Griffirths EJ, Halestrap AP. Protection by cyclosporin A of ischaemia/reperfusion induced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25:1461-9.
19. Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. Am J Physiol 1990;258:C755-86.
20. 2+ dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem J 1988;255:357-60.
21. 2+ and oxidative stress. FEBS Lett 1992;304(2,3):192-4.
22. Muller K, Siems WE, Grune T, Heinz D, Henke W, Jung K. Adaptational increase of liver glutathione content during long-term application of cyclosporin A may attenuate toxic side-effects. Cell Mol Biol 1992;38(7):729-38.
23. McGrath LT, Douglas AF, McClean E et al. Oxidative stress and erythrocyte membrane fluidity in patients undergoing regular dialysis. Clin Chim Acta 1995;235:179-88.
24. Cobas Fara, Roche Diagnostics, Welwyn Garden City, Hertfordshire, England, UK.
25. Goldberg DM, Spooner RJ. Glutathione reductase. In: Bergmeyer, editor. Methods of enzymatic analysis. New York: VCH, 1987;3:258-65.
26. Randox Laboratories Ltd, Ardmore, Diamond Road, Crumlin, Co. Antrim BT29 4QY, UK.
27. McCord JM, Fridovitch I. Superoxide dismutase: an enzymatic function for erythrocuprein (haemocuprein). J Biol Chem 1969;244:6049-55.
28. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterisation of erythrocyte glutathione peroxidase. J Lab Clin Invest 1967;70:158-69.
29. Hatam LJ, Kayden HJ. A high-performance liquid chromatographic method for the determination of tocopherol in plasma and cellular elements of the blood. J Lipid Res 1979;20:639-45.
30. Warwick GR. Enzymatic methods for quantification of lipoprotein lipids. In: Segrest JP, Albers JJ, editors. Methods in Enzymology, Vol. 128. Florida: Academic Press, 1986;101-10.
31. Taylor JE, Scott N, Bridges A, Henderson IS, Stewart WK, Belch JJF. Lipid peroxidation and antioxidants in continuous ambulatory dialysis patients. Perit Dial Internat 1992;12:252-6.
32. Durak I, Akyol O, Baseme G, Canbolat O, Kavatcu M. Reduced erythrocyte defence mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 1994;66:76-80.
33. Taylor JE, Scott N, Hill A et al. Oxygen free radicals and platelet and granulocyte aggregability in renal transplants. Transplantation 1993;55(3):500-4.
34. Van den Dorpel MA, Man in't Veld AJ, Levi M, Rischen-Vos J, Jansen H, Weimer W. Substantial improvement of lipid peroxidation and fibrinolysis after conversion from cyclosporin A to azathioprine. Renal Association Meeting. Oxford: 1996;6.
35. Hirano T, Honma M, Okra K, Sakurai E, Okochi Y, Kozaki M. Effects of highdose glucocorticoid on serum lipid-peroxide levels in acute renal-allograft rejection [Letter]. Clin Chim Acta 1987;164:111.
36. Connor HD, Gao W, Nukina S, Lemasters JJ, Mason RP, Thurman RG. Evidence that free radicals are involved in graft failure following orthoptic liver transplantation in the rat - an electron paramagnetic resonance spin trapping study. Transplantation 1992;54920:199-204.
37. Heberer M, Jorgensen J, Mihatsh MJ, Marx A, Landmann J. Protective effect of allipurinol and superoxide dismutase in renal isografts in cyclosporin A treated rats. Renal Failure 1991;13940:233-42.
38. Taniguchi N. Clinical significance of superoxide dismutases: changes in aging, diabetes, ischaemia and cancer. Adv Clin Chem 1992;29:1-59.
39. 2. Arch Biochem Biophys 1981;212:411-6.
40. Futenma A, Yamada H, Kitano M, Miyai H, Fukatsu A, Kato K. Plasma levels of superoxide dismutase and its isomers in patients with chronic renal disease. Jpn J Nephrol 1993;35(4):61-6.
41. Melissonon KG, Delidou AZ, Varsou AG, Begietti SS, Drivas GJ. Serum and erythrocyte glutathione reductase activity in chronic renal failure. Nephron 1981;28:76-9.
42. Bock A, Forchhammer K, Heider J, Boron C. Selenoprotein synthesis: an expansion of the genetic code. Trends. Biochem Sci 1991;Dec:463-7.
43. Mihatsch MJ, Ryffell B, Hermle M, Brunner FP, Thiel G. Morphology of cyclosporin nephrotoxicity in the rat. Clin Nephrol 1985;25(Suppl 1):S2-8.
44. Brown Z, Neild GH, Willoughby JJ, Somia NV, Cameron SJ. Increased factor VII as an index of vascular injury in cyclosporin nephrotoxicity. Transplantation 1986;42:150-3.
45. Shinitzky M, Barenholz Y Fluidity parameters of lipid regions determined by fluorescence polarisation. Biochim Biophys Acta 1978;515:367-94.
46. Block ER, Patel JM, Edwards D. Mechanism of hypoxic injury to pulmonary artery endothelial cell plasma membranes. Am Physiol Soc 1989;257:C223-31.
47. Agar NS, Board PG. Red blood cells of domestic animals. Amsterdam: Elsevier, 1983.
48. Haynes M, Fuller L, Haynes DH, Miller J. Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture. Immunol Lett 1985;11:343-9.
49. Stuhne-Sekalec L, Stanacev N. Liposomes as cyclosporin A carriers: ESR studies of cyclosporin A interaction with 1,2-dimethylOsn-3-phosphatidylglycerol liposomes. J Microencapsul (JMG) 1991;8(4):455-63.
50. +, K( + )-adenosine triphosphate activity in cultured hamster renal tubular cells. Toxicol Appl Pharmacol (VWO) 1994;125(2):176-83.